Our initial experience with PSMA PET in the workup of patients with biochemical failure after primary therapy for prostate cancer with no definitive metastatic disease on conventional workup has shown PSMA PET positivity in more than 90% of patients, with local recurrence or oligometastatic disease in over half of them. Here, FOLH1 is linked to prostate carcinoma.